Stock RXI PHARMACEUTICALS CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News RXi Pharmaceuticals Corp Nasdaq

Equities

US74979C3034

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for RXi Pharmaceuticals Corp
Apr. 02 North American Morning Briefing : Stocks Seen -2- DJ
Apr. 01 Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
AQ
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
AQ
National Spotlight Features Phio’s Innovative RNAi Technology Platform
AQ
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
GL
North American Morning Briefing : Stocks Seen -2-
DJ
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
AQ
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
CI
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
AQ
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research
CI
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders
MT
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
AQ
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
CI
HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating
MT
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
AQ
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
AQ
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
AQ
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. Stock
  5. News RXi Pharmaceuticals Corp